Please use this identifier to cite or link to this item: https://essuir.sumdu.edu.ua/handle/123456789/86179
Or use following links to share this resource in social networks: Recommend this item
Title Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study
Authors Gafanov, R.
Powles, T.B.
Bedke, J.
Stus, V.
Waddell, T.S.
Nosov, D.
Pouliot, F.
Soulieres, D.
Melichar, B.
Azevedo, S.
McDermott, R.S.
Vynnychenko, Ihor Oleksandrovych  
Borchiellini, D.
Markus, M.
Bondarenko, I.
Lin, J.
Burgents, J.
Molife, L.R.
Plimack, E.R.
Rini, B.
Keywords pembrolizumab
axitinib
sunitinib treatment
Type Conference Papers
Date of Issue 2021
URI https://essuir.sumdu.edu.ua/handle/123456789/86179
Publisher Elsevier
License Creative Commons Attribution 4.0 International License
Citation Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study / R. Gafanov, T. B. Powles, J. Bedke et al. // Annals of Oncology. — 2021. — Volume 32, Issue S5. — P. S 694. — https://doi.org/10.1016/j.annonc.2021.08.065
Abstract In the phase III KEYNOTE-426 study, pembrolizumab + axitinib showed significant improvement in OS, PFS, and ORR vs sunitinib in patients with RCC. This analysis assessed subsequent treatment in patients enrolled in KEYNOTE-426.
Appears in Collections: Наукові видання (МІ)

Views

Ukraine Ukraine
273

Downloads

Ukraine Ukraine
148

Files

File Size Format Downloads
Gafanov_et.al_Therapy.pdf 97,72 kB Adobe PDF 148

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.